Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories reported a sharp fall in profits for Q1 FY26 (quarter ended June 30, 2025) despite relatively stable standalone revenues. On a consolidated basis, operating revenue declined about 6.6% year-on-year to Rs. 42,524 lakhs, while net profit after minority interest fell roughly 70% to Rs. 1,075 lakhs from Rs. 3,617 lakhs a year ago, dragging EPS down to Rs. 0.20 from Rs. 0.71. Standalone revenue was almost flat at Rs. 39,128 lakhs, but standalone net profit dropped about 77% to Rs. 806 lakhs as expenses and finance costs rose. The Board also approved hiving off its Medical Devices Business into Morepen Medipath Limited (a subsidiary) on a slump sale basis, flagged as a material related party transaction needing shareholder approval, set a record date of August 30, 2025 for a final dividend, and re-appointed Mr. Sanjay Suri as Whole-Time Director for three years.
Sharp profit decline and margin compression on both standalone and consolidated books signal cost pressures and weaker profitability, which is likely negative for short-term investor sentiment. However, the proposed Medical Devices hive-off, the final dividend eligibility, and the consolidation change at Dr. Morepen Limited (shareholding cut from 80% to 19.94%) are structural events shareholders should track for their effect on future earnings and balance sheet.